However, the addition of osimertinib, the preferred EGFR inhibitor option for first-line treatment for EGFR mutation-positive advanced NSCLC, to the culture markedly enhanced CER-1236 T cell killing (Figures 5C and 5D), in line with the increases in target ligand.64 Here, EGFR is linked to non-small cell lung carcinoma.